“Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable ...

Osteoarthritis, the most common form of arthritis, is primarily caused by wear and tear on the protective layer of cartilage ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Japanese Patent Office issued a notice of allowance ...

Treatment with other antiobesity medications was not permitted; the use of other interventions for knee osteoarthritis was permitted. Although pain medication could be used throughout the trial ...

Treatment assignment was concealed until ... Secondary outcomes were tested in the following order: Hip Disability and Osteoarthritis Outcome Score in the five domains of pain, symptoms, function ...

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and ...

Subcutaneous semaglutide is currently marketed under the brand name Wegovy for chronic weight management and to reduce the risk of major adverse cardiovascular events in adults with established ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.

“Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body ...

New research shows that weight loss drugs semaglutide, known as Ozempic and Wegovy, not only aid in weight loss but also ...